Retatrutide is a synthetic peptide developed as a triple agonist, targeting the GLP-1, GIP, and glucagon receptors. This 5mg vial offers a lower-concentration option, well suited for preliminary research and dose-ranging studies investigating metabolic regulation and the structure–activity relationships of incretin-based peptides.

Each vial is synthesized using solid-phase peptide synthesis and verified by HPLC and mass spectrometry to ensure high purity and batch-to-batch consistency. Supplied as a white lyophilized powder, sealed under inert conditions for stability during storage and shipping.

For research use only. This product is intended strictly for laboratory and research purposes. It is not a drug, food, or cosmetic and is not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary use.